BSA
NBIX icon

Braun Stacey Associates’s Neurocrine Biosciences NBIX Stock Holding History

Braun Stacey Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-182,262
Closed -$25.9M – 116
2025
Q4 		$25.9M Sell
182,262
-765
-0.4% -$111K 0.84% 44
2025
Q3 		$25.7M Buy
183,027
+12,657
+7% +$1.71M 0.84% 45
2025
Q2 		$21.4M Buy
+170,370
New +$19.5M 0.77% 58
2019
Q3 		– Sell
-2,379
Closed -$201K – 121
2019
Q2 		$201K Sell
2,379
-74,148
-97% -$6.09M 0.01% 114
2019
Q1 		$6.74M Sell
76,527
-30,410
-28% -$2.54M 0.45% 93
2018
Q4 		$7.64M Sell
106,937
-45,637
-30% -$4.37M 0.61% 83
2018
Q3 		$18.8M Buy
152,574
+6,680
+5% +$758K 1.2% 22
2018
Q2 		$14.3M Buy
+145,894
New +$13.1M 0.97% 45

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Braun Stacey Associates's NBIX Position: Q1 2026 in Review

Braun Stacey Associates sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 182,262 shares — an estimated $25.9M sold.

Braun Stacey Associates first reported a position in NBIX in Q2 2018 and held it in 8 quarters. The position peaked at $25.9M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Braun Stacey Associates reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Braun Stacey Associates sold 182,262 Neurocrine Biosciences shares in Q1 2026, an estimated $25.9M.
  • Braun Stacey Associates first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 8 quarters.
  • Braun Stacey Associates's Neurocrine Biosciences position peaked at $25.9M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Braun Stacey Associates's 13F filing for Q1 2026, filed 22 Apr 2026.